Search Within

Department of Medicine

Formats
  1. Journal Article (19593)
  2. Meeting Abstract (16038)
  3. Review (1150)
  4. Book Section (934)
  5. Editorial (610)
  6. Research Letter (314)
  7. Conference Paper (301)
  8. Guidelines (295)
  9. Correspondence (236)
  10. Miscellaneous (90)
  11. Book Whole (61)
Groups
  1. Solid Tumor Oncology Division (22321)
  2. Hematologic Malignancies, Division of (13278)
  3. Center for Hematologic Malignancies (11061)
  4. GSK Faculty (10646)
  5. Survivorship Research (9330)
  6. Division of Subspecialty Medicine (7535)

More Groups

People
  1. Robert Motzer (1248)
  2. Howard Scher (1132)
  3. Sergio Giralt (1069)
  4. Miguel-Angel Perales (943)
  5. Clifford Hudis (905)
  6. Jedd Wolchok (905)

More People

Years
  1. 2025 (1071)
  2. 2024 (2291)
  3. 2023 (2452)
  4. 2022 (2621)
  5. 2021 (2534)
  6. 2020 (2563)

More Years

Publications
  1. Journal of Clinical Oncology (6125)
  2. Blood (3722)
  3. Annals of Oncology (1398)
  4. Cancer Research (1238)
  5. Clinical Cancer Research (902)
  6. Biology of Blood and Marrow Transplantation (679)

More Publications

Publishers
  1. American Society of Clinical Oncology (6458)
  2. Elsevier Inc. (4216)
  3. American Society of Hematology (4003)
  4. American Association for Cancer Research (2896)
  5. Oxford University Press (2286)
  6. Nature Publishing Group (2111)

More Publishers

Results (39622)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Efficacy and safety of trastuzumab deruxtecan among patients with HER2-expressing solid tumors: Biomarker and subgroup analyses from the cervical, endometrial, and ovarian cancer cohorts of the DESTINY-PanTumor02 study
    Meeting Abstract

    Makker, V.; Oaknin, A.; Manso, L.; González-Martín, A.; Lugowska, I.; Meric-Bernstam, F.; Lorusso, D.; Banerjee, S.; Liao, J.; Siena, S.; more...
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • Efficacy and safety of alpelisib plus olaparib versus chemotherapy among patients with platinum-resistant or refractory high-grade serous ovarian cancer without BRCA mutation: Primary analysis of the EPIK-O trial
    Meeting Abstract

    Konstantinopoulos, P.; Kim, J. W.; Freyer, G.; Lee, J. Y.; Gaba, L.; Grisham, R.; Colombo, N.; Wu, X.; Sehouli, J.; Cruz, F.; more...
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • Tumour dosimetry across 6 cycles of [(177)Lu]LuPSMA-617 in patients with metastatic castrationresistant prostate cancer: Results from the VISION substudy
    Meeting Abstract

    Herrmann, K.; Krause, B.; Chi, K.; Sartor, O.; Fizazi, K.; Morris, M. J.; De Bono, J.; Tagawa, S.; Kurth, J.; Eiber, M.; more...
    European Journal of Nuclear Medicine and Molecular Imaging (2024)

    Fulltext@MSK | Save
  • Results from CA240-0007, a phase 1/2 multiple expansion cohort study of BMS-986504 in patients (pts) with advanced solid tumors with homozygous MTAP deletion (MTAP-del)
    Meeting Abstract

    Rodon, J.; Jänne, P. A.; Leventakos, K.; George, B.; Henry, J. T.; Johnson, M. L.; Papadopoulos, K. P.; Batista, A. I.; Spira, C. P.; Zhao, Y.; more...
    European Journal of Cancer (2024)

    Fulltext@MSK | Save
  • Updated safety and efficacy from a phase 1 study of RMC-6236, a RAS (ON) multi-selective, tri-complex inhibitor, in patients with RAS mutant pancreatic ductal adenocarcinoma (PDAC)
    Meeting Abstract

    Wolpin, B.; Hong, D.; Spira, A.; Starodub, A.; Park, W.; Sommerhalder, D.; Valerin, J.; Barve, M.; Punekar, S.; Pelster, M.; more...
    European Journal of Cancer (2024)

    Fulltext@MSK | Save
  • PD-L1 ligation enhances NK cell anti-tumor function by inducing a metabolic shift
    Meeting Abstract

    Srpan, K.; Lupo, K.; Hsu, K.
    European Journal of Immunology (2024)

    Fulltext@MSK | Save
  • NEXUS-01, a phase 1 study of LY4052031, an antibody-drug conjugate targeting nectin-4 in participants with advanced or metastatic urothelial carcinoma or other solid tumors (trial in progress)
    Meeting Abstract

    Baldini, C.; Patnaik, A.; Lakhani, N.; Call, J.; Galsky, M.; Garmezy, B.; Wei, A.; Carter, L.; Powles, T.; Siefker-Radtke, A.; more...
    European Journal of Cancer (2024)

    Fulltext@MSK | Save
  • Targeted CRISPR-Knockout (KO) screening to identify FOXF1 regulators and therapeutic strategies in gastrointestinal stromal tumor (GIST)
    Meeting Abstract

    Tomas, F.; Cho, W. H.; Li, D.; Callychurn, V. R.; Wang, N.; Yu, C.; Chi, P.
    European Journal of Cancer (2024)

    Fulltext@MSK | Save
  • Tumor adaptation to PI3K inhibition and its stability increases as a function of time and is overcome by combined inhibiting Bcl2 family proteins
    Meeting Abstract

    Mukherjee, R.; Vanaja, K. G.; Sharma, M.; Solomon, H.; De Stanchina, E.; Chandarlapaty, S.; Rosen, N.
    European Journal of Cancer (2024)

    Fulltext@MSK | Save
  • Preliminary safety and anti-tumor activity of TYRA-300, a highly selective FGFR3 inhibitor, in participants with advanced solid tumors with activating FGFR3 mutations/fusions (SURF301)
    Meeting Abstract

    Tran, B.; Boni, A.; Hansen, A.; Boni, V.; Mantia, C.; Yu, E.; Weickhardt, A.; Robert, M.; Gupta, S.; Necchi, A.; more...
    European Journal of Cancer (2024)

    Fulltext@MSK | Save